Dubai Final-v20.indd - World Allergy Organization

ABstrACts
ABstrACts
2311
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1 inH) For THE ProPHYlaXiS oF aTTaCKS oF
HErEDiTarY angioEDEma (HaE) in PEDiaTriC SUBJECTS
Hurewitz, D. 1 , grant, J. A. 2 , Busse, P. 3 , Davis-lorton , m. 4 , Baker, J. 5 , riedl , m. 6 , Banerji, A. 7 , levy, r. 8 , Craig, t. J. 9 , Kalfus, i. 10 ,
Broom, C. 11 , Villano, s. 11 , Uknis, m. 11 , tillotson, g. 11 and the Cinryze study group
1 2 3 Allergy Clinic of tulsa, inc., tulsa, OK. University texas medical Branch, galveston, tX. mount sinai school of medicine, new York,
nY. 4Winthrop - University Hospital, mineola, nY. 5University of michigan, Ann Arbor, mi. 6UClA medical Center, los Angeles, CA.
7 8 9 massachusetts general Hospital, Boston, mA. Family Allergy and Asthma Center, PC, Atlanta, gA. Penn state University, Hershey,
PA. 10lev Pharmaceuticals, Plymouth meeting, PA. 11ViroPharma incorporated, Exton, PA.
introduction: HAE is an autosomal dominant disease of deficient functional C1 inhibitor (nf-C1 inH) manifested by attacks of
angioedema commonly involving the gastrointestinal lining, extremities, face, larynx, and genitalia. symptoms of HAE typically begin
in childhood and worsen around puberty. stanozolol is FDA approved for pediatric prophylaxis but has undesirable AEs, such as
masculinization, premature puberty, and premature epiphyseal plate closure. this subset analysis evaluates the use of nf-C1 inH for
routine prophylaxis in pediatric subjects with HAE